2009 Clinical Trials Data Terpenes 
The Cannigma
JANUARY 13, 2023
Based on the limited existing evidence, the best cannabis strain for migraines may be a Type II that includes both THC and CBD, and a terpene profile that includes beta-caryophyllene, myrcene, linalool, limonene, bisabolol, humulene or pinene. The study called out pinene, myrcene, and beta-caryophyllene as specifically useful terpenes.
The Cannigma
JULY 1, 2022
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TheAnswerPage
JANUARY 11, 2022
As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Since 2009, Dr. Fisher-Corn has served as Editor-in-Chief of TheAnswerPage.com.
Cannabis Law Report
OCTOBER 29, 2019
The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Fig 1: Sucralose (In Study).
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Originally a lawyer, Yang began working in startups and early stage growth companies as a founder or executive from 2000 to 2009.
Cannabis Law Report
NOVEMBER 24, 2021
At the same time, the outlook on cannabis research data is largely positive. Research into the plant’s chemical compounds has also revealed a rich array of terpenes and flavonoids that may also account for the plant’s therapeutic effects (Kotsirilos and McGregor 2021 ). Data collection.
Expert insights. Personalized for you.
132 
Let's personalize your content